Hôpital Européen Georges-Pompidou
- Address
- lock Available on a paid plan
Neoplasms (Oncology)
At Hôpital Européen Georges‑Pompidou the oncology unit conducts a broad portfolio of studies focused on solid tumors, evaluating novel systemic agents, immunotherapy combinations, and precision‑medicine approaches to improve survival and disease‑free outcomes.
- Adjuvant checkpoint inhibitor therapy after complete resection of lung cancer
- Dual‑immune checkpoint blockade versus standard surveillance in renal cell carcinoma
- Targeted ROS1 inhibitor efficacy in advanced non‑small cell lung cancer
- PARP inhibition combined with androgen deprivation in metastatic castration‑resistant prostate cancer
- Weekly dose‑dense carboplatin‑paclitaxel regimen for high‑risk ovarian cancer
The site supports 40 active trials led by 25 investigators, aiming to bring cutting‑edge cancer therapies to French patients.
Respiratory Tract Diseases
Research on pulmonary conditions includes interstitial lung disease, sarcoidosis, and idiopathic pulmonary fibrosis, with trials testing anti‑inflammatory biologics and novel antifibrotic agents to preserve lung function.
- Rituximab versus placebo for progressive interstitial lung disease
- OATD‑01 impact on granulomatous inflammation in active pulmonary sarcoidosis
- CAL101 evaluation of forced vital capacity in idiopathic pulmonary fibrosis
- MTX‑463 effect on lung function decline in fibrotic lung disease
These studies reflect the department’s commitment to advancing therapeutic options for patients with chronic respiratory disorders.
Immune System Diseases
The center investigates autoimmune vasculitis and related renal complications, seeking strategies to modulate immune suppression while minimizing adverse events.
- Immunosuppression withdrawal versus maintenance in ANCA‑associated vasculitis with end‑stage renal disease
- Dose individualization of fluoropyrimidines based on DPD deficiency
- Safety of sodium valproate for hearing preservation in Wolfram syndrome
By integrating biomarker‑driven dosing and targeted immunomodulation, the trials aim to improve quality of life for patients with complex immune disorders.
Cardiovascular Diseases
Clinical investigations address acute coronary events and arrhythmias, evaluating anticoagulation management technologies and novel therapeutic regimens to reduce thrombotic risk.
- Implantable monitoring device versus standard care for anticoagulation in acute coronary syndrome with new‑onset atrial fibrillation
- Comparative safety of antiplatelet strategies in patients with recent myocardial infarction
These projects underscore the hospital’s interdisciplinary approach to cardiovascular health, blending cardiology expertise with advanced trial design.
Digestive System Diseases
A series of gastrointestinal oncology trials explore chemotherapy optimization, biologic combinations, and molecularly guided therapies for colorectal, gastric, pancreatic, and anal cancers.
- Modified DCF induction followed by chemoradiotherapy for locally advanced anal squamous cell carcinoma
- FOLFOX with or without docetaxel in first‑line treatment of metastatic oesophago‑gastric adenocarcinoma
- Pembrolizumab plus XELOX or FOLFOX and bevacizumab in microsatellite‑stable colorectal cancer with high immune infiltrate
- Circulating tumor DNA‑guided adjuvant therapy decision in stage II colon cancer
- Hyperthermic intraperitoneal chemotherapy (HIPEC) versus standard surgery for ovarian cancer relapse
The oncology program leverages molecular profiling and innovative drug combinations to enhance outcomes across a spectrum of digestive malignancies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 11 therapeutic areas and 15 of 63 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 57 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 20 by active trials.
lock +19 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hôpital Européen Georges-Pompidou
lock Showing 1 of 42 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase III Double-Blind, Placebo-Controlled Study of Adjuvant Durvalumab in Resected Stage IB-IIIA Non-Small Cell Lung Cancer with PD-L1 Expression ≥25% | Clinipace Global Limited, Fundacion GECP, Intergroupe Francophone De Cancerologie Thoracique, NVALT-studies Stichting, Queen's University | Phase III | Not Recruiting | Mar 2015 | Mar 2025 |
IMP list
lock Showing 1 of 63 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 10 | Unknown | 2014-12-23 | 2026-02-19 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.